Check out market updates

MiRagen’s cobomarsen misses skin treatment target in Phase II trial for lymphoma

BOULDER — One of the most prominent drug candidates in the MiRagen Therapeutics Inc. (Nasdaq: MGEN) pipeline failed to show […]
Source: BizWest

Leave a Reply

Your email address will not be published. Required fields are marked *